Lantheus Holdings, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mary Anne Heino
- Full Time Employees
- 1,193
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 201 Burlington Road Bedford MA United States 01730
- IPO Date
- Jun 25, 2015
- CIK
- 0001521036
- Website
- lantheus.com
- Similar Companies
- Business
- Lantheus Holdings, Inc. is a global biopharmaceutical company specializing in the development, manufacturing, and commercialization of diagnostic imaging agents and radiopharmaceuticals. The company’s core product portfolio includes radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging, contrast agents for echocardiography such as DEFINITY® Vial, and generator systems like TechneLite® for technetium-99m production used in nuclear medicine. Lantheus also offers contract development and manufacturing organization (CDMO) services for diagnostic agents and specialty pharmaceuticals, supporting clinical development and commercial manufacturing. Its products primarily serve the oncology, cardiology, and neurology markets, aiding in the diagnosis and management of serious diseases. The company operates globally with headquarters in North Billerica, Massachusetts, and was founded in 1956. In the past two years, Lantheus has undergone significant strategic expansion through acquisitions and product pipeline growth. Notably, it acquired Evergreen Theragnostics in 2025 for $250 million upfront with additional milestone payments, enhancing its radiopharmaceutical capabilities by incorporating scalable manufacturing infrastructure and expanding its oncology diagnostic pipeline with products like OCTEVY™, a PET diagnostic for neuroendocrine tumors. Additionally, Lantheus completed the acquisition of Life Molecular Imaging in mid-2025 for up to $750 million, adding the FDA-approved F-18 PET agent Neuraceq used to detect beta-amyloid plaques in Alzheimer’s disease, a significant complement to its diagnostic portfolio. These acquisitions reinforce Lantheus' strategy to become a fully integrated radiopharmaceutical company encompassing drug development, manufacturing, and commercialization. The company has also announced plans to divest its SPECT business to focus on higher-growth radiopharmaceuticals. Lantheus continues to innovate in molecular imaging with a robust pipeline including new radiotracers targeting cancers and neurological conditions. It supports healthcare providers with clinical education and comprehensive solutions across the diagnostic imaging value chain. In 2025, the company implemented a $400 million stock repurchase program and adjusted its financial guidance reflecting short-term pressures but emphasizing long-term growth through its growing commercial portfolio and clinical assets. Leadership changes during 2025 include executive role shifts to strengthen commercial and operational capabilities. Lantheus is positioning itself as a leader in radiopharmaceutical innovation serving oncology, cardiology, and neurology markets globally.
Company News
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
Lantheus Reports Third Quarter 2026 Financial Results
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)
Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated “Hold” by Wall Street Analysts
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH